Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10

Large type 3 and type 4 gastric cancers (GC) have a significantly poor prognosis, primarily due to their high predisposition for peritoneal dissemination. The application of intraperitoneal chemotherapy has emerged as a viable therapeutic strategy for managing GC patients with peritoneal metastasis. This study is planned to enroll 37 resectable large type 3 or type 4 GC patients. These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study's primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events.<b>Clinical trial registration number:</b> ChiCTR2400083253 (https://www.chictr.org.cn).

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-10-08
DOI
https://doi.org/10.1080/14796694.2024.2400042
Citations
2
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10

Zhongyin Yang, Zhenglun Zhu, Ling-Quan Wang, Chao Yan et al.
2 citations
Future Oncology
Gastric Cancer Management and Outcomes
0.84
article

Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10

Zhongyin Yang, Zhenglun Zhu, Ling-Quan Wang, Chao Yan, Xuexin Yao, Yanan Zheng, Sheng Lu, Min Yan, Wentao Liu, Birendra Kumar Sah, Runhua Feng, Zhenggang Zhu, Hong Yuan, Zhijian Jin, Mingmin Chen, Jun Zhang, Min Shi, Changyu He, Zichen Hua, Zhentian Ni, Zhenjia Yu, Chen Li, Zhenqiang Wang
article en
2 citations

Abstract

Large type 3 and type 4 gastric cancers (GC) have a significantly poor prognosis, primarily due to their high predisposition for peritoneal dissemination. The application of intraperitoneal chemotherapy has emerged as a viable therapeutic strategy for managing GC patients with peritoneal metastasis. This study is planned to enroll 37 resectable large type 3 or type 4 GC patients. These patients are scheduled to undergo a treatment comprising preoperative chemotherapy with paclitaxel, oxaliplatin and S-1, followed by D2 gastrectomy, and concluding with postoperative treatments that include prophylactic intraperitoneal chemotherapy. The study's primary objective is to evaluate the 3-year peritoneal recurrence rate. Secondary objectives are to assess the 3-year disease-free survival, 3-year overall survival and to monitor the adverse events.<b>Clinical trial registration number:</b> ChiCTR2400083253 (https://www.chictr.org.cn).

Future OncologyVol. 20(36)
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN)
Good health and well-being
Openalex Percentile: Top 24%
Gastric Cancer Management and Outcomes
0.84
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.